Sana Biotechnology (NASDAQ:SANA) Trading Up 7.8% - Here's What Happened

Key Points

• Shares of Sana Biotechnology were trading up 7.8% to about $3.33 mid-day, with roughly 939,320 shares traded — a ~60% decline from its average daily volume.
• Analysts are mixed but collectively rate the stock a Moderate Buy with an average price target of $7.83, alongside several individual upgrades and downgrades.
• The company has a market cap near $876.7 million and remains loss-making after reporting Q results that missed estimates (EPS -$0.16 vs. -$0.13), while institutional investors hold about 88.2% of the shares and several large funds recently increased positions.

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) were up 7.8% during mid-day trading on Friday . The stock traded as high as $3.30 and last traded at $3.3310. Approximately 939,320 shares traded hands during trading, a decline of 60% from the average daily volume of 2,337,721 shares. The stock had previously closed at $3.09.

Analysts Set New Price Targets

A number of research firms have weighed in on SANA. Bank of America upped their target price on Sana Biotechnology from $6.00 to $7.00 and gave the stock a "buy" rating in a report on Tuesday, January 6th. Zacks Research lowered Sana Biotechnology from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, March 3rd. HC Wainwright decreased their price objective on Sana Biotechnology from $9.00 to $7.00 and set a "buy" rating for the company in a research note on Wednesday, March 4th. Wall Street Zen lowered Sana Biotechnology from a "hold" rating to a "sell" rating in a research note on Saturday, February 7th. Finally, Weiss Ratings reiterated a "sell (e+)" rating on shares of Sana Biotechnology in a report on Monday, December 29th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Sana Biotechnology has an average rating of "Moderate Buy" and an average price target of $7.83.

Sana Biotechnology Stock Up 6.3%

The business has a 50-day moving average price of $4.18 and a 200-day moving average price of $4.13. The firm has a market capitalization of $876.67 million, a price-to-earnings ratio of -3.40 and a beta of 1.96.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last posted its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.03). On average, equities research analysts forecast that Sana Biotechnology, Inc. will post -1.16 earnings per share for the current year.

Institutional Investors Weigh In On Sana Biotechnology

A number of large investors have recently modified their holdings of the business. Marex Group plc acquired a new position in shares of Sana Biotechnology during the second quarter valued at about $10,423,000. Balyasny Asset Management L.P. acquired a new stake in Sana Biotechnology in the 4th quarter worth approximately $6,834,000. Vanguard Group Inc. grew its position in Sana Biotechnology by 19.9% during the 3rd quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company's stock worth $32,408,000 after purchasing an additional 1,517,474 shares during the last quarter. JPMorgan Chase & Co. grew its position in Sana Biotechnology by 180.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company's stock worth $7,581,000 after purchasing an additional 1,375,029 shares during the last quarter. Finally, State Street Corp increased its stake in Sana Biotechnology by 20.6% during the 4th quarter. State Street Corp now owns 8,054,841 shares of the company's stock valued at $32,783,000 after purchasing an additional 1,374,300 shares in the last quarter. Hedge funds and other institutional investors own 88.23% of the company's stock.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company's core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.